• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高表达 BRCA1 基因的乳腺癌中增强的癌细胞增殖和侵袭表型抵消。

Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.

机构信息

Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY, 14263, USA.

Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, 036-8562, Japan.

出版信息

Breast Cancer Res Treat. 2024 Nov;208(2):321-331. doi: 10.1007/s10549-024-07421-8. Epub 2024 Jul 7.

DOI:10.1007/s10549-024-07421-8
PMID:38972017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11842165/
Abstract

PURPOSE

While comprehensive research exists on the mutation of the DNA repair gene BRCA1, limited information is available regarding the clinical significance of BRCA1 gene expression. Given that cancer cell proliferation is aggrevated by DNA repair, we hypothesized that high BRCA1 gene expression breast cancer (BC) might be linked with aggressive tumor biology and poor clinical outcomes.

METHODS

The cohorts: The Cancer Genome Atlas (TCGA, n = 1069), METABRIC (n = 1903), and SCAN-B (n = 3273) were utilzed to obtain data of 6245 BC patients.

RESULTS

BC patients without BRCA1 mutation exhibited higher BRCA1 expression, which was associated with DNA repair functionality. However, no such correlation was observed with BRCA2 expression. The association of high BRCA1 expression with cancer cell proliferation was evidenced by significant enrichment of cell proliferation-related gene sets, higher histological grade, and proliferation score. Furthermore, increased levels of homologous recombination deficiency, intratumoral heterogeneity, and altered fractions were associated with high BRCA1 expression. Moreover, BC with high BRCA1 expression exhibited reduced infiltration of dendritic cells and CD8 T-cells, while showing increased infiltration of Th1 cells. Surprisingly, BRCA1 expression was not associated with the survival of BC irrespective of the subtypes. Conversely, BC with low BRCA1 expression enriched cancer aggravating pathway gene sets, such as Cancer Stem Cell-related signaling (NOTCH and HEDGEHOG), Angiogenesis, Epithelial-Mesenchymal Transition, Inflammatory Response, and TGF-beta signaling.

CONCLUSION

Despite being linked to heightened proliferation of cancer cells and unassertive phenotype, BRCA1 expression did not show any association with survival in BC.

摘要

目的

虽然已经有大量关于 DNA 修复基因 BRCA1 突变的综合研究,但关于 BRCA1 基因表达的临床意义的信息有限。由于 DNA 修复会加剧癌细胞增殖,我们假设高 BRCA1 基因表达的乳腺癌(BC)可能与侵袭性肿瘤生物学和不良临床结局有关。

方法

本研究使用了三个队列的数据:癌症基因组图谱(TCGA,n=1069)、METABRIC(n=1903)和 SCAN-B(n=3273),共获得了 6245 例 BC 患者的数据。

结果

无 BRCA1 突变的 BC 患者表现出更高的 BRCA1 表达,这与 DNA 修复功能有关。然而,BRCA2 表达与这种相关性无关。高 BRCA1 表达与癌细胞增殖的相关性通过细胞增殖相关基因集的显著富集、更高的组织学分级和增殖评分得到证实。此外,同源重组缺陷、肿瘤内异质性和改变的分数增加与高 BRCA1 表达相关。此外,高 BRCA1 表达的 BC 表现为树突状细胞和 CD8 T 细胞浸润减少,而 Th1 细胞浸润增加。令人惊讶的是,BRCA1 表达与 BC 的生存无关,无论亚型如何。相反,低 BRCA1 表达的 BC 富集了促进癌症进展的途径基因集,如癌症干细胞相关信号(NOTCH 和 HEDGEHOG)、血管生成、上皮间质转化、炎症反应和 TGF-β信号。

结论

尽管 BRCA1 表达与癌细胞增殖增加和不活跃表型有关,但它与 BC 的生存无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/7ffabdfef193/nihms-2053348-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/88d58774ea00/nihms-2053348-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/dc222b035746/nihms-2053348-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/81630b2e54b0/nihms-2053348-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/24f0aef7a8eb/nihms-2053348-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/88eb50ea5132/nihms-2053348-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/1455f004237c/nihms-2053348-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/7ffabdfef193/nihms-2053348-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/88d58774ea00/nihms-2053348-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/dc222b035746/nihms-2053348-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/81630b2e54b0/nihms-2053348-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/24f0aef7a8eb/nihms-2053348-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/88eb50ea5132/nihms-2053348-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/1455f004237c/nihms-2053348-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5f0/11842165/7ffabdfef193/nihms-2053348-f0007.jpg

相似文献

1
Enhanced cancer cell proliferation and aggressive phenotype counterbalance in breast cancer with high BRCA1 gene expression.高表达 BRCA1 基因的乳腺癌中增强的癌细胞增殖和侵袭表型抵消。
Breast Cancer Res Treat. 2024 Nov;208(2):321-331. doi: 10.1007/s10549-024-07421-8. Epub 2024 Jul 7.
2
CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.CD133 表达与 DNA 修复能力降低、对 ER 阳性/HER2 阴性乳腺癌化疗反应更好和生存时间延长相关。
Breast Cancer Res Treat. 2024 Nov;208(2):415-427. doi: 10.1007/s10549-024-07434-3. Epub 2024 Jul 17.
3
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.DNA损伤反应标志物在BRCA突变的乳腺癌中差异表达。
Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.
4
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.BRCA1/BRCA2 缺陷与乳腺癌突变负担、PD-L1/PD-1 表达、免疫浸润和 T 细胞炎症特征的关联。
PLoS One. 2019 Apr 25;14(4):e0215381. doi: 10.1371/journal.pone.0215381. eCollection 2019.
5
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.BRCA1启动子高甲基化、53BP1蛋白表达及PARP-1活性作为乳腺癌DNA修复缺陷生物标志物的研究
BMC Cancer. 2013 Nov 5;13:523. doi: 10.1186/1471-2407-13-523.
6
Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.RAD21 增强型黏连蛋白表达与 BRCA2 和 BRCAX,但不是 BRCA1 家族性乳腺癌的不良预后相关。
Breast Cancer Res. 2012 Apr 26;14(2):R69. doi: 10.1186/bcr3176.
7
Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy.乳腺癌中的基因表达与较差的预后相关,但对化疗和免疫治疗的反应较好。
World J Oncol. 2025 Feb;16(1):120-130. doi: 10.14740/wjon1993. Epub 2025 Jan 13.
8
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.鼠 BRCA1 缺陷型乳腺肿瘤的蛋白质组学分析鉴定了具有潜在诊断和预后价值的人类乳腺癌 DNA 修复蛋白。
Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.
9
Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features.在乳腺癌中,Aurora-A/AURKA 的高表达与较年轻的年龄和侵袭性特征相关。
Breast Cancer Res. 2024 Aug 28;26(1):126. doi: 10.1186/s13058-024-01882-x.
10
Biological and clinical significance of PARP1 protein expression in breast cancer.PARP1蛋白表达在乳腺癌中的生物学及临床意义
Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.

引用本文的文献

1
Pan-cancer analysis of UGGT1 in human tumors and experimental validation in breast cancer.UGGT1在人类肿瘤中的泛癌分析及在乳腺癌中的实验验证
Sci Rep. 2025 Jul 24;15(1):26901. doi: 10.1038/s41598-025-12619-x.
2
Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor Microenvironment.间皮素(MSLN)在三阴性乳腺癌中高表达,并与细胞增殖增强和促炎性肿瘤微环境相关。
Ann Surg Oncol. 2025 Jun;32(6):4476-4486. doi: 10.1245/s10434-025-17117-y. Epub 2025 Mar 13.
3
Comprehensive Analysis of the Significance of Breast Cancer Gene 1 (BRCA-1) in Bladder Cancer.

本文引用的文献

1
E2F target score is associated with cell proliferation and survival of patients with hepatocellular carcinoma.E2F 靶评分与肝癌患者的细胞增殖和存活有关。
Surgery. 2023 Aug;174(2):307-314. doi: 10.1016/j.surg.2023.04.030. Epub 2023 May 15.
2
Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines.阑尾神经内分泌肿瘤的管理:当前指南见解
Cancers (Basel). 2022 Dec 31;15(1):295. doi: 10.3390/cancers15010295.
3
High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
乳腺癌基因1(BRCA - 1)在膀胱癌中的意义综合分析
Cancer Manag Res. 2024 Sep 30;16:1305-1319. doi: 10.2147/CMAR.S467817. eCollection 2024.
高 miR-99b 表达与乳腺癌细胞增殖及患者较差预后相关。
Am J Cancer Res. 2022 Oct 15;12(10):4840-4852. eCollection 2022.
4
Development of a novel BRCAness score that predicts response to PARP inhibitors.一种预测对PARP抑制剂反应的新型BRCAness评分的开发。
Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.
5
Low adipocyte hepatocellular carcinoma is associated with aggressive cancer biology and with worse survival.低脂肪细胞型肝细胞癌与侵袭性癌症生物学行为及较差的生存率相关。
Am J Cancer Res. 2022 Aug 15;12(8):4028-4039. eCollection 2022.
6
Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer.肿瘤内主要表达于内皮细胞的 PDGFB 基因与血管生成和淋巴管生成有关,但与乳腺癌的转移无关。
Breast Cancer Res Treat. 2022 Aug;195(1):17-31. doi: 10.1007/s10549-022-06661-w. Epub 2022 Jul 6.
7
NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation.NR2F1是一种肿瘤休眠标志物,主要在癌症相关成纤维细胞中表达,并与乳腺癌细胞增殖受抑制有关。
Cancers (Basel). 2022 Jun 15;14(12):2962. doi: 10.3390/cancers14122962.
8
Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.活性氧(ROS)的大量存在与乳腺癌的侵袭性、免疫反应和较差的生存有关。
Breast Cancer Res Treat. 2022 Jul;194(2):231-241. doi: 10.1007/s10549-022-06633-0. Epub 2022 May 31.
9
Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?早期三阴性乳腺癌的全身治疗降阶梯:新时代的曙光?
Cancers (Basel). 2022 Apr 7;14(8):1856. doi: 10.3390/cancers14081856.
10
DNA repair defects in cancer and therapeutic opportunities.癌症中的 DNA 修复缺陷与治疗机会。
Genes Dev. 2022 Mar 1;36(5-6):278-293. doi: 10.1101/gad.349431.122.